INFINITY PHARMACEUTICALS INC's ticker is INFI and the CUSIP is 45665G303. A total of 143 filers reported holding INFINITY PHARMACEUTICALS INC in Q4 2014. The put-call ratio across all filers is 2.93 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2023 | $2,979 | -56.5% | 14,150 | -66.9% | 0.00% | – |
Q1 2023 | $6,847 | -86.0% | 42,792 | -51.4% | 0.00% | – |
Q4 2022 | $48,871 | -58.6% | 88,055 | -11.3% | 0.00% | – |
Q3 2022 | $118,000 | +145.8% | 99,303 | +30.1% | 0.00% | – |
Q2 2022 | $48,000 | -36.8% | 76,303 | +15.2% | 0.00% | – |
Q1 2022 | $76,000 | -65.8% | 66,232 | -32.8% | 0.00% | – |
Q4 2021 | $222,000 | -59.1% | 98,587 | -37.9% | 0.00% | -100.0% |
Q3 2021 | $543,000 | +517.0% | 158,738 | +437.7% | 0.00% | – |
Q2 2021 | $88,000 | +51.7% | 29,519 | +8.7% | 0.00% | – |
Q4 2020 | $58,000 | +56.8% | 27,156 | -14.6% | 0.00% | – |
Q3 2020 | $37,000 | +362.5% | 31,794 | +249.8% | 0.00% | – |
Q2 2020 | $8,000 | 0.0% | 9,090 | 0.0% | 0.00% | – |
Q1 2020 | $8,000 | +300.0% | 9,090 | +461.5% | 0.00% | – |
Q3 2019 | $2,000 | -60.0% | 1,619 | -41.0% | 0.00% | – |
Q2 2019 | $5,000 | -73.7% | 2,745 | -72.9% | 0.00% | – |
Q1 2019 | $19,000 | +72.7% | 10,117 | +4.2% | 0.00% | – |
Q4 2018 | $11,000 | -54.2% | 9,706 | +8.3% | 0.00% | – |
Q3 2018 | $24,000 | -17.2% | 8,962 | -40.3% | 0.00% | – |
Q2 2018 | $29,000 | -63.3% | 15,000 | -60.3% | 0.00% | -100.0% |
Q1 2018 | $79,000 | +295.0% | 37,783 | +150.7% | 0.00% | – |
Q3 2017 | $20,000 | -35.5% | 15,072 | -34.5% | 0.00% | – |
Q4 2016 | $31,000 | +29.2% | 23,009 | +50.3% | 0.00% | – |
Q3 2016 | $24,000 | +1100.0% | 15,304 | +748.8% | 0.00% | – |
Q2 2016 | $2,000 | – | 1,803 | +60000.0% | 0.00% | – |
Q1 2016 | $0 | -100.0% | 3 | -100.0% | 0.00% | -100.0% |
Q4 2015 | $162,000 | -25.7% | 20,623 | -20.0% | 0.00% | -33.3% |
Q3 2015 | $218,000 | -39.9% | 25,767 | -22.2% | 0.00% | -40.0% |
Q2 2015 | $363,000 | +11.3% | 33,132 | +42.2% | 0.01% | 0.0% |
Q1 2015 | $326,000 | -16.0% | 23,292 | +1.3% | 0.01% | -16.7% |
Q4 2014 | $388,000 | +331.1% | 22,997 | +241.8% | 0.01% | +500.0% |
Q3 2014 | $90,000 | -71.8% | 6,728 | -73.1% | 0.00% | -80.0% |
Q2 2014 | $319,000 | -62.2% | 25,039 | -64.8% | 0.01% | -64.3% |
Q1 2014 | $845,000 | -72.2% | 71,101 | -67.7% | 0.01% | -69.6% |
Q4 2013 | $3,037,000 | +222.7% | 219,893 | +307.8% | 0.05% | +155.6% |
Q3 2013 | $941,000 | +331.7% | 53,925 | +302.5% | 0.02% | +260.0% |
Q2 2013 | $218,000 | – | 13,399 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,354,963 | $38,132,000 | 1.80% |
Orbimed Advisors | 4,520,800 | $73,201,000 | 1.55% |
QVT Financial LP | 1,326,610 | $21,480,000 | 1.44% |
BB BIOTECH AG | 1,089,828 | $17,646,000 | 1.27% |
Meditor Group Ltd | 250,000 | $4,048,000 | 0.55% |
Perimeter Capital Partners, LLC | 159,915 | $2,589,000 | 0.50% |
EMERALD MUTUAL FUND ADVISERS TRUST | 156,808 | $2,539,000 | 0.43% |
Broadfin Capital, LLC | 117,172 | $1,897,000 | 0.37% |
OXFORD ASSET MANAGEMENT LLP | 811,331 | $13,184,000 | 0.36% |
Baker Brothers Advisors | 1,016,433 | $16,458,000 | 0.33% |